Navigation Links
SIRO ClinPharm and Advanced Clinical Trial Solutions Ink Strategic Alliance
Date:4/17/2009

Alliance provides global oncology clinical development solutions in North America, Europe and India.

PRINCETON, N.J., April 17 /PRNewswire/ -- SIRO ClinPharm (SIRO), a leading multinational Contract Research Organization (CRO), today announced the signing of a strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, NJ, USA, a service provider in oncology drug development with a business concentration in North America. This alliance will enable SIRO to expand its oncology clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO's clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.

"We are delighted to add ACT Solution's North American expertise in our service offering to our customers, said Dr Chetan Tamhankar, COO of SIRO ClinPharm group. "This alliance is the first step for SIRO in creating delivery capabilities in North America."

"We are excited about aligning our strengths in oncology with SIRO's international delivery capabilities," said Patricia Devitt Risse, Pharm. D, President of ACT Solutions LLC. "This step addresses the changing dynamics of the clinical research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India," she explained.

According to Patricia Terek, President of SIRO ClinPharm, USA, "This step will help meet the growing needs of our oncology customers to have access to operational capabilities in North America. We are excited to offer the clinical development expertise of ACT Solutions in North America to our customers globally."

About SIRO

SIRO is a leading multinational contract research organization. With a presence in over 15 countries across North America, Europe and Asia, SIRO offers global bio-technology and pharmaceutical companies end to end clinical trial services. Established in year 1996, SIRO has emerged as a leading name for high speed and optimal cost of conducting clinical research. More information about the SIRO group is available at www.siroclinpharm.com

About Advanced Clinical Trial Solutions LLC

Advanced Clinical Trial Solutions LLC (ACT Solutions) is a privately held company that is devoted to operational excellence in global oncology drug development. ACT Solutions is staffed solely with experienced oncology personnel that has enabled it to grow its business annually and to establish strategic partnerships to expand the scope of the ACT Solutions service offerings. More information about ACT Solutions is available at www.actsolutions.org


'/>"/>
SOURCE SIRO ClinPharm
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
2. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
3. Advanced Life Sciences Announces Filing of Shelf Registration Statement
4. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
5. METTLER TOLEDO and AAPS: Utilization of Process Modeling and Advanced Process Control in QbD based Drug Development and Manufacturing
6. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
7. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
8. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
9. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
10. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):